Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 19, Number 1—January 2013

Research

Invasive Pneumococcal Disease after Routine Pneumococcal Conjugate Vaccination in Children, England and Wales

Shamez N. LadhaniComments to Author , Mary P.E. Slack, Nick J. Andrews, Pauline A. Waight, Ray Borrow, and Elizabeth Miller
Author affiliations: Author affiliations: Health Protection Services Colindale, London, UK (S.N. Ladhani, M.P.E. Slack, N.J Andrews, P.A Waight, E. Miller); Health Protection Agency, Manchester, UK (R. Borrow)

Main Article

Figure

IPD clinical cases in PCV7-eligible children since PCV7 introduction, England and Wales, September 4, 2006–March 31, 2010. A) Distribution of cases. Black bar sections, bacteremia; dark gray bar sections, lower respiratory tract infection; light gray bar sections, meningitis; white bar sections, other. B) Proportion of serotyped cases caused by PCV7 serotypes in healthy children (dashed line) and children with comorbidities (solid line). The prevalences of comorbidity among IPD cases during the

Figure. . . IPD clinical cases in PCV7-eligible children since PCV7 introduction, England and Wales, September 4, 2006–March 31, 2010. A) Distribution of cases. Black bar sections, bacteremia; dark gray bar sections, lower respiratory tract infection; light gray bar sections, meningitis; white bar sections, other. B) Proportion of serotyped cases caused by PCV7 serotypes in healthy children (dashed line) and children with comorbidities (solid line). The prevalences of comorbidity among IPD cases during the 4 time periods were 13,5%, 17.7%, 17.0%, and 10.7%, and the case-fatality rates were 5.6%, 4.3%, 4.3%, and 3.0%, respectively. *Data included for 7 months only. IPD, invasive pneumococcal disease; PCV7, 7-valent pneumococcal conjugate vaccine.

Main Article

TOP